LRRK2 and Parkinson disease: It has been reported that the PD AAO of LRRK2 p.G2019S carriers is modified by the Dynamin-3 (DNM3) rs2421947 variant; GG rs2421947 homozygotes have been reported to have a median disease onset 12.5 years younger than other p.G2019S carriers (Trinh et al., 2016).